F	-0	)R	Μ	4	
J	-				_

Check this box if no
longer subject to Section
16. Form 4 or Form 5
obligations may
continue. See Instruction
1(b)

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

SEC 1474 (9-02)

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)								1			
1. Name and Address of Reporting Person – Urdea Michael S		2. Issuer Name and Ticker or Trading Symbol PRESSURE BIOSCIENCES INC [PBIO]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) 100 BOUNCE MEADOWS DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 06/11/2018						(specify below)	)		
(Street) ALAMO, CA 94507	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
(Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if Code (A) or Disposed of (D)				<ol> <li>Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</li> </ol>	Ownership Form:	Beneficial Ownership			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	( <i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb	er	6. Date Exercisa	ble and	7. Title and A	mount	8. Price of	9. Number of	10.	11. Nature
	Conversion		Execution Date, if					Expiration Date		of Underlying		Derivative		Ownership	
		(Month/Day/Year)		Code		Derivati		(Month/Day/Yea		Securities					Beneficial
	Price of Derivative		(Month/Day/Year)	(Instr. 8		Securitie				(Instr. 3 and 4	)	(Instr. 5)	Beneficially Owned	Derivative	Ownership (Instr. 4)
	Security					Acquired (A) or	1							Security: Direct (D)	(Instr. 4)
	Security					Disposed	l of							or Indirect	
						(D)							Transaction(s)	(I)	
						(Instr. 3,	4,						(Instr. 4)	(Instr. 4)	
					_	and 5)									
											Amount				
									Expiration	Title	or Number				
								Exercisable	Date	THE	of				
				Code	v	(A)	(D)				Shares				
SERIES AA															
CONVERTIBLE	¢ 2.5	06/11/2019		T		20.20		0(111/2010	06/11/2019	COMMON	20.200	¢ 2 500	20.20	D	
PREFERRED	\$ 2.5	06/11/2018		J		20.20		06/11/2018	06/11/2019	STOCK	20,200	\$ 2,500	20.20	D	
STOCK															
COMMON										COMMON					
STOCK	\$ 3.5	06/11/2018		J		20,200		06/11/2018	06/11/2023	STOCK	20,200	<u>(1)</u>	20,200	D	
WARRANT										STOCK					
COMMON										COMMON					
STOCK	\$ 3.5	06/11/2018		J		2,739		03/31/2016(1)			2,739	(1)	2,739	D	
WARRANT	ψ 5.5	00/11/2010				2,759		05/51/2010	00/01/2021	STOCK	2,759		2,107	D	

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Urdea Michael S 100 BOUNCE MEADOWS DRIVE ALAMO, CA 94507	Х						

## **Signatures**

/s/ Michael S Urdea	06/13/2018	
**Signature of Reporting Person	Date	

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On June 11, 2018, Pressure BioSciences, Inc. (the "Issuer") entered into a letter agreement with Mr. Urdea (the "Reporting Person"). The Reporting Person previously held a convertible debenture with a face value of \$50,600 (the "Debenture") and warrants to purchase common stock (the "Debenture Warrants"). Pursuant to the letter agreement, the Reporting Person agreed to convert the principal due to him pursuant to the Debenture into shares of Series AA Convertible Preferred Stock with a conversion price of \$2.50 per share. The Reporting Person was also: (a) issued amended Debenture Warrants (originally issued on March 31, 2016) such that the exercise price is now \$3.50 per share; and (b) issued a new warrant with an exercise price of \$3.50 per share to purchase such number of shares of common stock as equal 100% of the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received as a result of the Debenture conversion.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.